As many as 150 applications are stuck at evaluation stage, says official.
Ranbaxy's US factory, Ohm Laboratories, is learnt to have got a clean chit from the American regulator. This US facility was under surveillance of the Food and Drug Administration (FDA) since the end of 2012.
Happy hours, a discount concept popular across bars, restaurants and multiplexes, is now catching up in the health care sector, too.
Deepak Fertiliser's promoter might offer to buy Saroj Poddar's stake.
The country's drug companies have attracted the highest number of enforcements from the American drug regulator in 2013, a year that has seen the US Food and Drug Administration turning stricter to ensure compliance levels and quality of medicines.
DCGI, health ministry initiate dialogues with foreign regulators, try to understand global best practices
The move comes in the wake of many facilities of Ranbaxy in India being barred by the US Food and Drugs Administration for supplying medicines to the US.
Import alert on Ranbaxy's Mohali unit; Strides' injectible arm gets warning letter
Medicines, including antibiotics, contraceptives and anti-diabetic drugs, were found to be out of stock at various places around Delhi.
The management hopes to clinch a deal by year-end, failing which even a shut down of the fortnightly cannot be ruled out, according to a top official, who did not want to be named.
Remittance into India from foreign countries has already seen a jump of 25% in the last two months
.jpg)
According to sources, the company has identified smaller markets such as Peru, which do not contribute significantly to profits, where it might shut shop in the near term.
Though the current framework applies to online advertisements as well, these pilot projects would lead to tighter screening on the Internet.
.jpg)
Firms are mandated to change prices of medicines within 45 days of NPPA's notification.
A probe finds several pharma majors in breach of the law; and in turn they blame the government.
.jpg)
The move is expected to delay the introduction of low-priced medicines in the market.
Companies asked to give data for three batches instead of one; move may lead to significant rise in development cost of generics
Cover inadequate for even one refinery.
The razor maker suffered a major jolt after the Securities Appellate Tribunal had quashed an appeal it filed against the regulator, which had earlier rejected Gillette's plan entailing reclassification of promoter holdings to comply with the public shareholding norms.
Face NPPA fine for overcharging on anti-asthma drug
© 2025 Rediff.com - Investor Information - Advertise with us - Disclaimer - Privacy Policy - Sitemap - Feedback - About us - Terms of use - Grievances